Submit a Biologics License Application for nomlabofusp
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 12 Feb 2024
- Due
- 31 Dec 2025
- Checked
- 1 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“targeting a BLA submission in the second half of 2025.”
What we found
Evidence strength A What the grades mean
The company did not submit the BLA in the second half of 2025 as originally targeted, instead updating its guidance in January 2026 to a planned submission in the second quarter of 2026.
-
A Larimar Therapeutics, Inc. 8-K filed 2026-01-12
“Path to Planned BLA Submission in Q2 2026” ✓ confirmed on the page
Market reaction: the shares moved +2.9% against the S&P 500 over the three sessions around the disclosure (9 Jan 2026 to 14 Jan 2026). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +181 days
- 2 versions
-
Version 1 · original · stated 12 Feb 2024
Deadline 31 Dec 2025 (“in the second half of 2025”) · wording aspirational
-
Version 2 · stated 30 Apr 2025
Deadline 31 Dec 2025 (“by year-end 2025”) · wording expected
“BLA seeking accelerated approval planned to be submitted by year-end 2025”
-
Version 3 · stated 23 Jun 2025
Deadline 30 Jun 2026 (“Q2 2026”) · wording expected
“BLA Submission Seeking Accelerated Approval Expected Q2 2026”
-
Version 4 · stated 14 Aug 2025
Deadline 30 Jun 2026 (“second quarter 2026”) · wording firm
“BLA seeking accelerated approval on track to be submitted in the second quarter 2026 to include adults and children.”
-
Version 5 · stated 29 Sep 2025
Deadline 30 Jun 2026 (“Q2 2026”) · wording aspirational
“Continue targeting BLA submission Q2 2026”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory submission
- Indicative materiality
- High rules
- Action
- Submit
- Deliverable
- Biologics License Application
- Language
- Aspirational (“aims”, “intends”)
- In the company’s control
- Medium
- Specificity
- Medium
- Conditional
- Yes: subject to regulatory approval
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Larimar Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-LRMR-002979 · Corrections policy